3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
16
Unknown
9
Not yet recruiting
8
Enrolling by invitation
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
1
Interventions
Cisplatin
4
130-nm albumin-bound paclitaxel
3
camrelizumab
2
Oxaliplatin
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Laparoscopy
2
Bevacizumab
2
trilaciclib
1
trastuzumab deruxtecan
1
toripalimab
1
selinexor
1
sacituzumab govitecan
1
ribociclib
1
olaparib
1
nimotuzumab
1
lenvatinib
1
fluorodopa F 18
1
durvalumab
1
decitabine and cedazuridine drug combination
1
dalpiciclib
1
cemiplimab
1
carfilzomib
1
apatinib
1
anlotinib
1
abemaciclib
1
Valacyclovir
1
Temozolomide
1
Taxes
1
Surgical Procedures, Operative
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Enrolling by invitation
×
dalpiciclib
×
Clear all
NCT06650748
2026-03-17
NeoMARS
Peking University
Phase 2
Enrolling by invitation
100 enrolled